Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B0XK
|
|||
| Former ID |
DNC000039
|
|||
| Drug Name |
1-furan-2-yl-3-pyridin-2-yl-propenone (FPP-3)
|
|||
| Synonyms |
FPP 028; 86969-15-5; BRN 5552278; 4-Ethyl-4,7-dihydro-2-phenylpyrazolo(1,5-a)pyrimidin-7-one; FPP-028; 4-Ethyl-2-phenyl-pyrazolo(1,5-a)pyrimidin-7(4H)-one; 4,7-Dihydro-4-ethyl-2-phenyl-pyrazolo(1,5-a)pyrimidin-7-one; Pyrazolo(1,5-a)pyrimidin-7(4H)-one, 4-ethyl-2-phenyl-; AC1Q6I4H; CHEMBL45806; AC1L375B; 4-ethyl-2-phenylpyrazolo[1,5-a]pyrimidin-7(4h)-one; CTK5F7460; DTXSID70236016; ZINC5957034; LS-129307; 4-ethyl-2-phenylpyrazolo[1,5-a]pyrimidin-7-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H13N3O
|
|||
| Canonical SMILES |
CCN1C=CC(=O)N2C1=CC(=N2)C3=CC=CC=C3
|
|||
| InChI |
1S/C14H13N3O/c1-2-16-9-8-14(18)17-13(16)10-12(15-17)11-6-4-3-5-7-11/h3-10H,2H2,1H3
|
|||
| InChIKey |
JEWOUZIOCRUZPT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 86969-15-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Arachidonate 5-lipoxygenase (5-LOX) | Target Info | Inhibitor | [1] |
| BioCyc | Aspirin-triggered lipoxin biosynthesis | |||
| Resolvin D biosynthesis | ||||
| Leukotriene biosynthesis | ||||
| Lipoxin biosynthesis | ||||
| Aspirin triggered resolvin D biosynthesis | ||||
| Aspirin triggered resolvin E biosynthesis | ||||
| KEGG Pathway | Arachidonic acid metabolism | |||
| Metabolic pathways | ||||
| Serotonergic synapse | ||||
| Ovarian steroidogenesis | ||||
| Toxoplasmosis | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Pathwhiz Pathway | Arachidonic Acid Metabolism | |||
| WikiPathways | Vitamin D Receptor Pathway | |||
| Arachidonic acid metabolism | ||||
| Eicosanoid Synthesis | ||||
| Selenium Micronutrient Network | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The anti-angiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced ... Vascul Pharmacol. 2009 Mar-Apr;50(3-4):123-31. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.